Carrol D'Sa1, Helen C Fox1, Adam K Hong1, Ralph J Dileone1, Rajita Sinha2. 1. Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut. 2. Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut. Electronic address: rajita.sinha@yale.edu.
Abstract
BACKGROUND: Cocaine dependence is associated with high relapse rates, but few biological markers associated with relapse outcomes have been identified. Extending preclinical research showing a role for central brain-derived neurotrophic factor (BDNF) in cocaine seeking, we examined whether serum BDNF is altered in abstinent, early recovering, cocaine-dependent individuals and whether it is predictive of subsequent relapse risk. METHODS: Serum samples were collected across three consecutive mornings from 35 treatment-engaged, 3-week-abstinent cocaine-dependent inpatients (17 males/18 females) and 34 demographically matched hospitalized healthy control participants (17 males/17 females). Cocaine-dependent individuals were prospectively followed on days 14, 30, and 90 posttreatment discharge to assess cocaine relapse outcomes. Time to cocaine relapse, number of days of cocaine use (frequency), and amount of cocaine use (quantity) were the main outcome measures. RESULTS: High correlations in serum BDNF across days indicated reliable and stable serum BDNF measurements. Significantly higher mean serum BDNF levels were observed for the cocaine-dependent patients compared with healthy control participants (p < .001). Higher serum BDNF levels predicted shorter subsequent time to cocaine relapse (hazard ratio: 1.09, p < .05), greater number of days (p < .05), and higher total amounts of cocaine used (p = .05). CONCLUSIONS: High serum BDNF levels in recovering cocaine-dependent individuals are predictive of future cocaine relapse outcomes and may represent a clinically relevant marker of relapse risk. These data suggest that serum BDNF levels may provide an indication of relapse risk during early recovery from cocaine dependence.
BACKGROUND:Cocaine dependence is associated with high relapse rates, but few biological markers associated with relapse outcomes have been identified. Extending preclinical research showing a role for central brain-derived neurotrophic factor (BDNF) in cocaine seeking, we examined whether serum BDNF is altered in abstinent, early recovering, cocaine-dependent individuals and whether it is predictive of subsequent relapse risk. METHODS: Serum samples were collected across three consecutive mornings from 35 treatment-engaged, 3-week-abstinent cocaine-dependent inpatients (17 males/18 females) and 34 demographically matched hospitalized healthy control participants (17 males/17 females). Cocaine-dependent individuals were prospectively followed on days 14, 30, and 90 posttreatment discharge to assess cocaine relapse outcomes. Time to cocaine relapse, number of days of cocaine use (frequency), and amount of cocaine use (quantity) were the main outcome measures. RESULTS: High correlations in serum BDNF across days indicated reliable and stable serum BDNF measurements. Significantly higher mean serum BDNF levels were observed for the cocaine-dependent patients compared with healthy control participants (p < .001). Higher serum BDNF levels predicted shorter subsequent time to cocaine relapse (hazard ratio: 1.09, p < .05), greater number of days (p < .05), and higher total amounts of cocaine used (p = .05). CONCLUSIONS: High serum BDNF levels in recovering cocaine-dependent individuals are predictive of future cocaine relapse outcomes and may represent a clinically relevant marker of relapse risk. These data suggest that serum BDNF levels may provide an indication of relapse risk during early recovery from cocaine dependence.
Authors: Ghazaleh Sadri-Vakili; Vidhya Kumaresan; Heath D Schmidt; Katie R Famous; Prianka Chawla; Fair M Vassoler; Ryan P Overland; Eva Xia; Caroline E Bass; Ernest F Terwilliger; R Christopher Pierce; Jang-Ho J Cha Journal: J Neurosci Date: 2010-09-01 Impact factor: 6.167
Authors: A Sartorius; R Hellweg; J Litzke; M Vogt; C Dormann; B Vollmayr; H Danker-Hopfe; P Gass Journal: Pharmacopsychiatry Date: 2009-11-18 Impact factor: 5.788
Authors: Doris E Payer; Arian Behzadi; Stephen J Kish; Sylvain Houle; Alan A Wilson; Pablo M Rusjan; Junchao Tong; Peter Selby; Tony P George; Tina McCluskey; Isabelle Boileau Journal: Neuropsychopharmacology Date: 2013-08-07 Impact factor: 7.853
Authors: Wendy J Lynch; Alexis B Peterson; Victoria Sanchez; Jean Abel; Mark A Smith Journal: Neurosci Biobehav Rev Date: 2013-06-24 Impact factor: 8.989
Authors: Justin C Strickland; Jean M Abel; Ryan T Lacy; Joshua S Beckmann; Maryam A Witte; Wendy J Lynch; Mark A Smith Journal: Drug Alcohol Depend Date: 2016-04-21 Impact factor: 4.492